Spots Global Cancer Trial Database for Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
Official Title: A Phase II, Multicentre, Open-label Study of Cabozantinib as 2nd Line Treatment in Subjects With Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors.
Study ID: NCT03945773
Interventions
Study Description
Brief Summary: The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted therapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
SALK - Salzburger Landesklinik, Salzburg, , Austria
CHRU Besançon, Besançon, , France
Centre Jean Perrin, Clermont-Ferrand, , France
Centre Léon Bérard, Lyon, , France
Institut Paoli Calmettes, Marseille, , France
Institut de Cancérologie de Lorraine, Nancy, , France
CHU de Nîmes - Institut de Cancérologie du Gard, Nîmes, , France
Institut Mutualiste Montsouris, Paris, , France
Centre Hospitalier Lyon Sud, Pierre-Bénite, , France
Institut de Cancérologie de l'Ouest, Saint-Herblain, , France
CHU Strasbourg, Strasbourg, , France
Institut Claudius Régaud, Toulouse, , France
Gustave Roussy, Villejuif, , France
Universitätsmedzin Charité, Berlin, , Germany
University Hospital Carl Gustav Carus Dresden, Dresden, , Germany
Universitätsklinikum Essen, Essen, , Germany
University Cancer Center Hamburg Eppendorf, Hamburg, , Germany
Medizinische Hochschule Hannover, Hannover, , Germany
Klinikum Der Friedrich-Schiller-Universitaet Jena, Jena, , Germany
Universitätsklinikum Schleswig-Holstein, Lübeck, , Germany
Otto-von-Guericke-Universität University hospital Magdeburg, Magdeburg, , Germany
University, Hospital Münster, Münster, , Germany
Caritas Krankenhaus St.Josef Klinik für Urologie, Regensburg, , Germany
University Hospital Tuebingen, Tübingen, , Germany
The Netherlands Cancer Institute - Oncology, Amsterdam, , Netherlands
Maxima Medisch Centrum, Eindhoven, , Netherlands
Leiden University Medical Center, Leiden, , Netherlands
Universitair Medisch Centrum Utrecht, Utrecht, , Netherlands
Hospital de La Santa Creu i Sant Pau, Barcelona, , Spain
Hospital Lucus Augusti, Lugo, , Spain
M.D. Anderson Center Madrid, Madrid, , Spain
Hospital Universitario 12 de Octubre, Madrid, , Spain
Universitätsspital Bern, Inselspital, Bern, , Switzerland
Centre Hospitalier Universitaire Vaudois, Lausanne, , Switzerland
Kantonsspital St. Gallen, Saint Gallen, , Switzerland
Western General Hospital - Edinburgh Cancer Centre, Edinburgh, , United Kingdom
Beatson West of Scotland Cancer Centre, Glasgow, , United Kingdom
The Christie NHS Foundation Trust, Manchester, , United Kingdom
Mount Vernon Hospital, Northwood, , United Kingdom
Royal Cornwall Hospital (RCH) - Sunrise Centre, Truro, , United Kingdom
Contact Details
Name: Ipsen Medical Director
Affiliation: Ipsen
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
